This study is a prospective, dual arm, open Ib/II phase clinical trial, with the main objective of exploring the safety and efficacy of Adebrelimab combined with Apatinib and Lrinotecan liposome for second-line treatment of advanced gastric cancer.
The study is divided into two stages. The first stage is the safety introduction period, which includes 6 patients. Observe whether the subjects experience dose limiting toxicity (DLT) during the observation period. If no subjects experience DLT during the observation period, the study enters the next stage. The dose of Lrinotecan liposome used during the safety introduction period is 80mg/m2, and the DLTs observation period is 1 cycle. If the patient cannot tolerate it, the dose will be reduced to 60mg/m2.
In the second stage, advanced gastric cancer subjects who have progressed to first-line treatment will be included in two cohorts: those who have previously received immune checkpoint inhibitor therapy and have first-line PFS\>7m (cohort 1) and those who have received standard systemic chemotherapy (cohort 2). 30 subjects will be included in each population, and a total of 66 subjects are planned to be enrolled.
The study includes a screening period (from the signing of the informed consent form by the subjects to the first treatment, not exceeding 28 days), a treatment period (Adebrelimab combined with Apatinib and Lrinotecan liposome), and a follow-up period (including safety and survival follow-up).
Age range: 18 to 75 years old, both male and female are acceptable;
Patients with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology;
Patients who have only received one failed systemic treatment for advanced diseases in the past; After undergoing immunotherapy, the PFS of the treatment regimen containing immune checkpoint inhibitors must be greater than 7 months;
According to the evaluation criteria for solid tumor efficacy 1.1 (RECIST v1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located within the previously irradiated area can also be selected as target lesions if progression is confirmed);
History of gastrointestinal perforation and/or fistula within 6 months prior to the first use of medication;
There is uncontrollable pleural effusion, pericardial effusion, or peritoneal effusion that requires repeated drainage;
Have a history of allergies to any component of Adebrelimab in the past;
Received any other investigational drug within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug;
Parallel
Adebrelimab + Apatinib + Lrinotecan liposome
DrugAdebrelimab 1200 mg, iv. q3w Apatinib 250 mg po qd Lrinotecan liposome 80mg/m2, iv. q3w Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years.
Progress Free Survival（PFS）
Median overall survival (mOS)
Objective response rate (ORR)
Disease Control Rate（DCR）
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Click on the lead sponsor to view all of their trials.
Xianglin Yuan
Lead sponsor
Huazhong University of Science and Technology
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
